Modified DRPT better for detecting primary angle closure

Article

Conducting a modified dark room provocative test (DRPT) is better for the diagnosis of primary angle closure, compared to gonioscopic angle assessment.

Conducting a modified dark room provocative test (DRPT) is better for the diagnosis of primary angle closure, compared to gonioscopic angle assessment, reveals a study in the Journal of Glaucoma.

Dr Dejiao Li led a cross-sectional observational prospective clinical study on 76 eyes of 76 patients. The anterior chamber angle configuration was measured in a light room and then after three minutes of dark adaptation using anterior segment optical coherence tomography (AS-OCT).

In light room conditions at baseline and after 1.5 hours of dark adaptation gonioscopy and Perkin's applanation tonometry were performed. The DRPT was identified as positive if intraocular pressure (IOP) increased by ≥8 mmHg after 1.5 hours of dark adaptation.

There were a significant number of eyes with an increased number of closed angle quadrants for the OCT examination at 3 minutes of dark adaptation, compared to gonioscopy at 1.5 hours of dark adaptation. For AS-OCT the area under the receiver operator characteristics curve was significantly larger, compared to gonioscopy.

A modified DRPT in combination with an anterior chamber angle assessment by OCT at 3 minutes of dark adaptation demonstrated a higher diagnostic precision for primary angle closure.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.